TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Most patients with colorectal cancer die as a result of the disease spreading to other organs. However, no prevalent mutations have been associated with metastatic colorectal cancers. Instead, particular features of the tumour microenvironment, such as lack of T-cell infiltration, low type 1 T-helper cell (T H 1) activity and reduced immune cytotoxicity or increased TGFβ levels predict adverse outcomes in patients with colorectal cancer. Here we analyse the interplay between genetic alterations and the tumour microenvironment by crossing mice bearing conditional alleles of four main colorectal cancer mutations in intestinal stem cells. Quadruple-mutant mice developed metastatic intestinal tumours that display key hallmarks of human microsatellite-stable colorectal cancers, including low mutational burden, T-cell exclusion and TGFβ-activated stroma. Inhibition of the PD-1-PD-L1 immune checkpoint provoked a limited response in this model system. By contrast, inhibition of TGFβ unleashed a potent and enduring cytotoxic T-cell response against tumour cells that prevented metastasis. In mice with progressive liver metastatic disease, blockade of TGFβ signalling rendered tumours susceptible to anti-PD-1-PD-L1 therapy. Our data show that increased TGFβ in the tumour microenvironment represents a primary mechanism of immune evasion that promotes T-cell exclusion and blocks acquisition of the T H 1-effector phenotype. Immunotherapies directed against TGFβ signalling may therefore have broad applications in treating patients with advanced colorectal cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Blockade of the TGFβ signaling pathway promotes enough T cell infiltration to make tumors sensitive to PD-1 therapy [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“Cell analysis of human and mouse CRC specimens showed that CAF is a major contributor to TGF-β production [39].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“It has been demonstrated in a variety of tumor models, including CRC models, that activation of CAF may induce PD-1 and CTLA-4 expression on relevant immune cells, which leads to tumor insensitivity to immunotherapy or recurrence [39,304,305,306].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [39]
In the citing paper
“A landmark study from 2018 demonstrated that TGF-β contributes to immune exclusion in colorectal liver metastasis and that inhibition of the TGF-β receptor 1 using the drug galunisertib enhanced tumorous infiltration with T cells, inhibited outgrowth of liver metastases and synergised with anti-PD-L1 therapy to eradicate established lesions.161”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [161]
In the citing paper
“leading to the proposition that combined TGFβ targeting and immune checkpoint blockade may represent an attractive therapeutic strategy for CMS4 colorectal cancer (34).”
From Clinical Challenges of Consensus Molecular Subtype CMS4 Colon Cancer in the Era of Precision Medicine (2024) · cites this paper as [34]
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Fitting Linear Mixed-Effects Models Using lme4
Bates, D., Mächler, M., Bolker, B., & Walker, S. (2015) · Journal of Statistical Software · doi:10.18637/jss.v067.i01 · Cited by 86,835
lmerTest Package: Tests in Linear Mixed Effects Models
Kuznetsova, A., Brockhoff, P. B., & Christensen, R. H. B. (2017) · Journal of Statistical Software · doi:10.18637/jss.v082.i13 · Cited by 24,346
ggplot2: Elegant Graphics for Data Analysis
Wickham, H. (2009) · doi:10.1007/978-0-387-98141-3 · Cited by 14,447
Data Analysis Using Regression and Multilevel/Hierarchical Models
Gelman, A., & Hill, J. (2006) · doi:10.1017/cbo9780511790942 · Cited by 13,597
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cited by
Items 201–300 of 1,002
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy
Li, J., Eu, J. Q., Kong, L. R., Wang, L., Lim, Y. C., Goh, B. C., & Wong, A. L. A. (2020) · Molecules · doi:10.3390/molecules25204831 · Cited by 159
van Staalduinen, J., Baker, D., ten Dijke, P., & van Dam, H. (2018) · Oncogene · doi:10.1038/s41388-018-0378-x · Cited by 158
The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response
Boustani, J., Grapin, M., Laurent, P.-A., Apétoh, L., & Mirjolet, C. (2019) · Cancers · doi:10.3390/cancers11060860 · Cited by 201
“Anti-TGFβ: RT triggers the activation of TGFβ, an immunosuppressive cytokine, which in turn promotes DNA damage repair and impairs the antigen-presenting function of DCs, and the functional differentiation of T cells into effectors [75,76].”
BackgroundBlocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor
Bai, X., Yi, M., Jiao, Y., Chu, Q., & Wu, K. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s224013 · Cited by 153
Molecular stratification within triple-negative breast cancer subtypes
Wang, D., Jiang, Z., Ben‐David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-55710-w · Cited by 178
Orgaz, J. L., Crosas-Molist, E., Sadok, A., Perdrix-Rosell, A., Maiques, O., Rodriguez-Hernandez, I., Monger, J., Mele, S., Georgouli, M., Bridgeman, V., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.003 · Cited by 151
“Therefore, blocking ROCK-myosin II reduces immunosuppressive microenvironments, improving anti-PD-1 action on pre-existing T cells (Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundCancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
Impairment of NKG2D-Mediated Tumor Immunity by TGF-β
Lazarova, M., & Steinle, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02689 · Cited by 149
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy
Álvarez-Varela, A., Novellasdemunt, L., Barriga, F. M., Hernando‐Momblona, X., Cañellas-Socias, A., Cano-Crespo, S., Sevillano, M., Cortina, C., Stork, D., Morral, C., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00402-0 · Cited by 164
Self-citationCancer Immunotherapy: Beyond Checkpoint Blockade
Dougan, M. L., Dranoff, G., & Dougan, S. K. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055552 · Cited by 164
Sakemura, R. L., Hefazi, M., Siegler, E. L., Cox, M. J., Larson, D. P., Hansen, M. J., Roman, C. M., Schick, K. J., Can, İ., Tapper, E. E., et al. (2022) · Blood · doi:10.1182/blood.2021012811 · Cited by 165
Cancer-associated fibroblasts: how do they contribute to metastasis?
Kwa, M. Q., Herum, K. M., & Brakebusch, C. (2019) · Clinical & Experimental Metastasis · doi:10.1007/s10585-019-09959-0 · Cited by 169
Stüber, T. N., Monjezi, R., Wallstabe, L., Kühnemundt, J., Nietzer, S., Dandekar, G., Wöckel, A., Einsele, H., Wischhusen, J., & Hudecek, M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000676 · Cited by 163
Chen, X., & Song, E. (2022) · 癌症:英文版 · doi:10.1002/cac2.12316 · Cited by 163
“For adaptive immunity, excessive TGFβ represents a primary mechanism of immune evasion that hinders DC maturation and T cell activation but promotes Treg expansion and T cell exclusion [105].”
BackgroundIFNγ signaling integrity in colorectal cancer immunity and immunotherapy
Du, W., Frankel, T. L., Green, M., & Zou, W. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00735-3 · Cited by 143
Mechanisms of organ fibrosis: Emerging concepts and implications for novel treatment strategies
Lurje, I., Gaisa, N. T., Weiskirchen, R., & Tacke, F. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101191 · Cited by 161
Chen, B., Gao, A., Tu, B., Wang, Y., Yu, X., Wang, Y., Xiu, Y., Wang, B., Wan, Y., & Huang, Y. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120187 · Cited by 151
Cancer immunotherapy comes of age and looks for maturity
Finck, A., Gill, S. I., & June, C. H. (2020) · Nature Communications · doi:10.1038/s41467-020-17140-5 · Cited by 142
Immune regulation of metastasis: mechanistic insights and therapeutic opportunities
Blomberg, O. S., Spagnuolo, L., & de Visser, K. E. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.036236 · Cited by 148
“The aberrant cytokine production driving immune recruitment and polarization occurs by cancer cells directly, or through increased cytokine expression in the TME by, for instance, fibroblasts (Erez et al., 2010; Tauriello et al., 2018) and immune cells.”
Limagne, E., Thibaudin, M., Nuttin, L., Spill, A., Derangère, V., Fumet, J.-D., Amellal, N., Peranzoni, E., Cattan, V., & Ghiringhelli, F. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0228 · Cited by 142
Tumor Plasticity and Resistance to Immunotherapy
Horn, L. A., Fousek, K., & Palena, C. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.02.001 · Cited by 156
IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction
Shiri, A. M., Zhang, T., Bedke, T., Zazara, D. E., Zhao, L., Lücke, J., Sabihi, M., Fazio, A., Zhang, S., Tauriello, D. V. F., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.12.015 · Cited by 158
Self-citationIntracellular and extracellular TGF-β signaling in cancer: some recent topics
Miyazono, K., Katsuno, Y., Koinuma, D., Ehata, S., & Morikawa, M. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0646-8 · Cited by 140
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Wang, M., Zhai, X., Li, J., Guan, J., Xu, S., Li, Y., & Zhu, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670391 · Cited by 162
“Several preclinical model studies have shown that a combination of certain cytokine drugs and ICIs can improve the prognosis (31, 32).”
BackgroundAdvanced and Innovative Nano-Systems for Anticancer Targeted Drug Delivery
Tang, L., Li, J., Zhao, Q., Pan, T., Zhong, H., & Wang, W. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081151 · Cited by 139
Yamamoto, Y., Kasashima, H., Fukui, Y., Tsujio, G., Yashiro, M., & Maeda, K. (2022) · Cancer Science · doi:10.1111/cas.15609 · Cited by 171
Metelli, A., Wu, B. X., Riesenberg, B., Guglietta, S., Huck, J. D., Mills, C., Li, A., Rachidi, S., Krieg, C., Rubinstein, M. P., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay4860 · Cited by 139
“In addition, TGF-1 promotes immune exclusion from tumors by creating a collagen and fibroblast barrier that shields tumors from immune infiltration (9, 10).”
BackgroundJena, B. C., Sarkar, S., Rout, L., & Mandal, M. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.002 · Cited by 151
TGFβ control of immune responses in cancer: a holistic immuno-oncology perspective
Nixon, B. G., Gao, S., Wang, X., & Li, M. O. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00796-z · Cited by 154
Huang, M.-Y., Jiang, X.-M., Wang, B.-L., Sun, Y., & Lu, J.-J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107694 · Cited by 136
The developmental origin of brain tumours: a cellular and molecular framework
Azzarelli, R., Simons, B. D., & Philpott, A. (2018) · Development · doi:10.1242/dev.162693 · Cited by 135
“Such a possibility has been suggested by work in other tissues but remains open for investigation in the nervous system (Burger and Peled, 2009; Calabrese et al., 2007; Tauriello et al., 2018).”
BackgroundHossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
“Coadministration of TGF‐β blocker and anti‐PD‐L1 antibodies triggered robust antitumor immunity.(361,362) Collectively, the inevitable contribution of cytokines to T‐cell exclusion and immunosuppressive TME may lead to the rationale for the development of”
BackgroundSymphony of nanomaterials and immunotherapy based on the cancer–immunity cycle
Li, Q., Shi, Z., Zhang, F., Zeng, W., Zhu, D., & Mei, L. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.031 · Cited by 138
Hu, Q., Zhu, Y., Mei, J., Liu, Y. L., & Zhou, G. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01717-y · Cited by 181
“The role of CAFs in ECM remodeling through TGF-β signaling inhibits the efficacy of immunotherapy in multiple cancers, including colorectal cancer, urothelial carcinoma, and pancreatic cancer [135–137].”
A Probiotic Spore‐Based Oral Autonomous Nanoparticles Generator for Cancer Therapy
Song, Q., Zheng, C., Jia, J., Zhao, H., Feng, Q., Zhang, H., Wang, L., Zhang, Z., & Zhang, Y. (2019) · Advanced Materials · doi:10.1002/adma.201903793 · Cited by 136
Tissue-Specific Roles of NKT Cells in Tumor Immunity
Terabe, M., & Berzofsky, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01838 · Cited by 151
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Recent Findings in the Regulation of Programmed Death Ligand 1 Expression
Shen, X., Zhang, L., Li, J., Li, Y., Wang, Y., & Xu, Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01337 · Cited by 139
“TGFβ inhibitor and PD-L1 blockade together provoke vigorous antitumor immune response and tumor regression (189, 190).”
BackgroundLi, J., Yuan, S., Norgard, R. J., Yan, F., Sun, Y. H., Kim, I.-K., Merrell, A. J., Sela, Y., Jiang, Y., Bhanu, N. V., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0519 · Cited by 133
“Further examination of the RNA-seq data also identified SMAD4, which has recently been implicated in suppressing antitumor immunity in PDA and other types of cancers (11, 58, 59), as a possible mediator of KDM3A’s immune-regulatory activity.”
MethodA Wnt-Induced Phenotypic Switch in Cancer-Associated Fibroblasts Inhibits EMT in Colorectal Cancer
Mosa, M. H., Michels, B. E., Menche, C., Nicolas, A. M., Darvishi, T., Greten, F. R., & Farin, H. F. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0263 · Cited by 130
“In colorectal cancer, a mesenchymal-rich stroma has been associated with poor prognosis (7–9) and an immunosuppressive environment (10).”
BackgroundTGF-β signaling in cell fate control and cancer
Yu, Y., & Feng, X. (2019) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2019.07.007 · Cited by 138
VISTA: Coming of age as a multi-lineage immune checkpoint
ElTanbouly, M. A., Schaafsma, E., Noelle, R. J., & Lines, J. L. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13415 · Cited by 126
Horn, L. A., Chariou, P. L., Gameiro, S. R., Qin, H., Iida, M., Fousek, K., Meyer, T. J., Cam, M., Flies, D., Langermann, S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci155148 · Cited by 127
“Several studies have now linked a gene signature of TGF-β activation in tumors with T cell exclusion and lack of responses to ICB therapy (15–17).”
CAFs orchestrates tumor immune microenvironment—A new target in cancer therapy?
Zhang, C., Fei, Y., Wang, H., Hu, S., Liu, C., Hu, R., & Du, Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1113378 · Cited by 127
“It has been demonstrated that increased CAF-derived TGF-β secretion is associated with decreased CD8 T cell accumulation in metastatic colorectal cancer and urothelial cancer as well as diminished sensitivity to immune checkpoint medications (Thomas and Massagué, 2005; Tauriello et al., 2018).”
BackgroundPI3Kβ controls immune evasion in PTEN-deficient breast tumours
Bergholz, J. S., Wang, Q., Wang, Q., Ramseier, M. L., Prakadan, S. M., Wang, W., Fang, R., Kabraji, S. K., Zhou, Q., Gray, G. K., et al. (2023) · Nature · doi:10.1038/s41586-023-05940-w · Cited by 152
TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Principe, D. R., Park, A., Dorman, M. J., Kumar, S., Viswakarma, N., Rubin, J., Torres, C., McKinney, R., Munshi, H. G., Grippo, P. J., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0850 · Cited by 126
Cancer-Associated Fibroblasts: Versatile Players in the Tumor Microenvironment
Ganguly, D., Chandra, R., Karalis, J. D., Teke, M. E., Aguilera, T. A., Maddipati, R., Wachsmann, M., Ghersi, D., Siravegna, G., Zeh, H. J., et al. (2020) · Cancers · doi:10.3390/cancers12092652 · Cited by 136
“How CAFs influence CD8+ T cells was shown in a murine model of colorectal cancer that demonstrated that CAF-derived TGF-β promoted CD8+ T cells exclusion from the TME, ultimately driving immune evasion and metastasis [120].”
BackgroundNew Approaches on Cancer Immunotherapy
Cha, J., Chan, L.-C., Song, M. S., & Hung, M. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036863 · Cited by 148
“Indeed, the authors demonstrated that combined inhibition of TGF-β and PD-L1 eliminated established metastases in a preclinical mouse model of colorectal cancer (Tauriello et al. 2018).”
BackgroundTGF-β Inhibition and Immunotherapy: Checkmate
Ganesh, K., & Massagué, J. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.037 · Cited by 124
“Tauriello et al. contribute further depth to the analysis of TGFβ in immunotherapy response by using a sophisticated array of genetically engineered and organoid transplantation mouse models of metastatic colorectal cancer (CRC).”
ResultInfluentialLiu, C., Lai, H., & Chen, T. (2020) · ACS Nano · doi:10.1021/acsnano.9b10103 · Cited by 130
Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives
Said, S. S., & Ibrahim, W. N. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041143 · Cited by 146
“A study on advanced colorectal cancer (CRC) demonstrated the depletion of T-cell infiltration through increased TGF-ß levels, which provoked immune suppression.”
BackgroundWang, S., Hossain, M. Z., Shinozuka, K., Shimizu, N., Kitada, S., Suzuki, T., Ichige, R., Kuwana, A., & Kobayashi, H. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112363 · Cited by 124
Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment
Zhu, S., Wang, Y., Tang, J., & Cao, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074477 · Cited by 155
Cancer Metabolism Drives a Stromal Regenerative Response
Schwörer, S., Vardhana, S. A., & Thompson, C. B. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.01.015 · Cited by 123
“, 2007); as a result, TGFβ production is associated with an inferior response to immunotherapy (Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundThe Remarkable Plasticity of Macrophages: A Chance to Fight Cancer
Bercovici, N., Guérin, M. V., Trautmann, A., & Donnadieu, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01563 · Cited by 122
Principe, D. R., Narbutis, M., Kumar, S., Park, A. J., Viswakarma, N., Dorman, M. J., Kamath, S. D., Grippo, P. J., Fishel, M. L., Hwang, R. F., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2959 · Cited by 134
Farin, H. F., Mosa, M. H., Ndreshkjana, B., Grebbin, B. M., Ritter, B., Menche, C., Kennel, K. B., Ziegler, P. K., Szabó, L., Bollrath, J., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0050 · Cited by 120
“Importantly, inhibition of TGFβ signaling in fibroblasts enables T-cell infiltration and responsiveness to checkpoint inhibition in advanced, metastatic non-MSI tumors (10).”
BackgroundInfluentialXiang, X., Niu, Y., Wang, Z.-H., Ye, L., Peng, W., & Zhou, Q. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.006 · Cited by 138
Takasaka, N., Seed, R. I., Cormier, A., Bondesson, A. J., Lou, J., Elattma, A., Ito, S., Yanagisawa, H., Hashimoto, M., Ma, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122591 · Cited by 119
“Increased penetration of immune cells to the tumor center from the tumor periphery is a hallmark of an effective tumor immune response and has been reported to be inhibited by TGF-β (4, 29).”
BackgroundInfluentialLi, Z., Song, W., Rubinstein, M., & Liu, D. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0684-3 · Cited by 119
Combination therapies with HSP90 inhibitors against colorectal cancer
Kryeziu, K., Bruun, J., Guren, T. K., Sveen, A., & Lothe, R. A. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.002 · Cited by 127
QuPath: The global impact of an open source digital pathology system
Humphries, M. P., Maxwell, P., & Salto‐Tellez, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.01.022 · Cited by 151
Kasashima, H., Duran, A., Martinez-Ordoñez, A., Nakanishi, Y., Kinoshita, H., Linares, J. F., Reina-Campos, M., Kudo, Y., L’Hermitte, A., Yashiro, M., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2020.10.014 · Cited by 118
Self-citationPredictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 134
Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0086 · Cited by 117
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
Cohen, R., Rousseau, B., Vidal, J., Colle, R., Diaz, L. A., & André, T. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00690-0 · Cited by 131
Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapy
Zhao, H., Wei, J., & Sun, J. M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107101 · Cited by 134
Wang, Y., Zhong, X., He, X., Hu, Z., Huang, H., Chen, J., Chen, K., Zhao, S., Wei, P., & Li, D. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02729-7 · Cited by 112
“Its high expression blocks the initiation of CD4+ Th1 cells and weakens cytotoxic responses, thus facilitating LM and leading to a poor prognosis [107, 108].”
BackgroundIntegrin-Mediated TGFβ Activation Modulates the Tumour Microenvironment
Brown, N. F., & Marshall, J. F. (2019) · Cancers · doi:10.3390/cancers11091221 · Cited by 116
SOX17 enables immune evasion of early colorectal adenomas and cancers
Goto, N., Westcott, P. M. K., Goto, S., Imada, S., Taylor, M. S., Eng, G., Braverman, J., Deshpande, V., Jacks, T., Agudo, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07135-3 · Cited by 116
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Turning tumors from cold to inflamed to improve immunotherapy response
Gerard, C. L., Delyon, J., Wicky, A. M., Homicskó, K., Cuendet, M. A., & Michielin, O. A. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102227 · Cited by 131
Puttock, E. H., Tyler, E. J., Manni, M., Maniati, E., Butterworth, C., Ramos, M. B., Peerani, E., Hirani, P., Gauthier, V., Liu, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38093-5 · Cited by 139
“1), we next evaluated whether this association resulted from the composition of ECM, using a decellularized tissue model of tumor ECM, made from a tissue library of 39 human omental ovarian metastatic tumor samples (Supplementary Dataset 5, Fig.”
InfluentialThe Role of TGF-β and Its Receptors in Gastrointestinal Cancers
Luo, J., Chen, X., & Li, P. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.11.010 · Cited by 122
Strating, E., Verhagen, M. P., Wensink, G. E., Dünnebach, E., Wijler, L. A., Aranguren, I., la Cruz, A. S. D., Peters, N. A., Hageman, J. H., van der Net, M. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1053920 · Cited by 136
Cancer Extracellular Matrix Proteins Regulate Tumour Immunity
Gordon-Weeks, A. N., & Yuzhalin, A. E. (2020) · Cancers · doi:10.3390/cancers12113331 · Cited by 132
“This is supported by spatial analysis of cancers demonstrating correlation between loose ECM structures or the presence of specific ECM proteins and immune cell abundance [71,74–77], as well as the resistance of cancers demonstrating excessive ECM deposition to immune checkpoint inhibition [78,79].”
BackgroundSow, H., Ren, J., Camps, M., Ossendorp, F., & ten Dijke, P. (2019) · Cells · doi:10.3390/cells8040320 · Cited by 112
“The antitumor activity of this combination therapy is consistent with the findings of multiple recent studies using immunogenic tumor models which demonstrated the improvement of anti-PD-L1 mAb when it is combined TGF-β receptor kinase inhibitor galunisertib [45,46].”
ResultWnt Signaling in 3D: Recent Advances in the Applications of Intestinal Organoids
Merenda, A., Fenderico, N., & Maurice, M. M. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.10.003 · Cited by 121
“Multiple studies have revealed that patient-derived tumor organoids retain organ site-specific histological and genetic traits, and can exhibit metastatic behavior when transplanted into immunocompromised mice [67,68].”
BackgroundMMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy
Owyong, M., Chou, J., van den Bijgaart, R. J. E., Kong, N., Efe, G., Maynard, C., Talmi-Frank, D., Solomonov, I., Koopman, C. D., Hadler‐Olsen, E., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201800226 · Cited by 116
“Because MMP9 is a known activator of TGFβ (Tauriello et al, 2018), therapy targeting active MMP9 in combination with checkpoint inhibitors is warranted as a future direction.”
BackgroundInfluentialFollicular helper-T cells restore CD8 + -dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
Niogret, J., Berger, H., Rébé, C., Mary, R., Ballot, E., Truntzer, C., Thibaudin, M., Dérangère, V., Hibos, C., Hampe, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002157 · Cited by 149
Determinants and functions of CAFs secretome during cancer progression and therapy
Linares, J., Marín-Jiménez, J. A., Badia-Ramentol, J., & Calon, A. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.621070 · Cited by 110
“Characteristically, this effect was associated with a reduction of fibroblasts activation and an increased anti-tumor immune genes expression (Holmgaard et al., 2018; Mariathasan et al., 2018; Tauriello et al., 2018).”
BackgroundSelf-citationDirecting Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 152
Coagulome and the tumor microenvironment: an actionable interplay
Galmiche, A., Rak, J., Roumenina, L. T., & Saidak, Z. (2022) · Trends in cancer · doi:10.1016/j.trecan.2021.12.008 · Cited by 122
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 124
Linares, J., Sallent-Aragay, A., Badia-Ramentol, J., Recort-Bascuas, A., Méndez, A., Manero-Rupérez, N., Re, D. L., Rivas, E. I., Guiu, M., Zwick, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36334-1 · Cited by 109
“Drawingmodified from Tauriello et al.17. b Biological activity of oxaliplatin against HT29-M6, PDO and CCD-18Co.”
Self-citation3D models in the new era of immune oncology: focus on T cells, CAF and ECM
Modugno, F. D., Colosi, C., Trono, P., Antonacci, G., Ruocco, G., & Nisticò, P. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1086-2 · Cited by 121
The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System
Romeo, E. L., Caserta, C. A., Rumio, C., & Marcucci, F. (2019) · Cells · doi:10.3390/cells8050460 · Cited by 121
Omatsu, M., Nakanishi, Y., Iwane, K., Aoyama, N., Duran, A., Muta, Y., Martinez-Ordoñez, A., Han, Q., Agatsuma, N., Mizukoshi, K., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41095-y · Cited by 109
“The “ CMS4_UP ” and “ CMS4_DOWN ” signatures were generated, as previously described 4,17 .”
The Immune Microenvironment and Cancer Metastasis
El-Kenawi, A., Hänggi, K., & Ruffell, B. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037424 · Cited by 121
“The ability of EMT to promote an immunosuppressive environment is likely furtheraugmentedbyhighproduction of transforming growth factor (TGF)-β, which can lead to the exclusion of lymphocytes from tumor beds (Mariathasan et al. 2018; Tauriello et al. 2018) and regulate the activation state of most immune cells.”
BackgroundCancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 126
Zhou, X., Ni, Y., Liang, X., Lin, Y., An, B., He, X., & Zhao, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915094 · Cited by 145
“Meanwhile, transforming growth factor-beta (TGF-b) produced by cancer-associated fibroblasts (CAFs) was capable of preventing T cells from entering tumor tissue (78).”
BackgroundAkiyama, T., Yasuda, T., Uchihara, T., Yasuda‐Yoshihara, N., Tan, B. J. Y., Yonemura, A., Semba, T., Yamasaki, J., Komohara, Y., Ohnishi, K., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1890 · Cited by 116
Molecular imaging biomarkers for immune checkpoint inhibitor therapy
van de Donk, P. P., de Ruijter, L. K., Hooge, M. N. L., Brouwers, A. H., van der Wekken, A. J., Oosting, S. F., Fehrmann, R. S. N., de Groot, D. J. A., & de Vries, E. G. E. (2020) · Theranostics · doi:10.7150/thno.38339 · Cited by 112
“Currently, several trials are conducted with TGF-β inhibitors, some in combination with ICI, as preclinical findings have shown an increase in effector T cells in the tumor (103).”
BackgroundRecent developments with immunotherapy for hepatocellular carcinoma
Waidmann, O. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1499722 · Cited by 107
“An escape mechanism leading to immune evasion driven by tumor cells is activation of transforming growth factor-β (TGFβ) signaling pathway [39,40].”
BackgroundChallenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape
Mulet-Margalef, N., Linares, J., Badia-Ramentol, J., Jimeno, M., Sanz, C., Mozo, J. L. M., & Calon, A. (2023) · Cancers · doi:10.3390/cancers15041022 · Cited by 124
Self-citationKok, V. C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00268 · Cited by 113
Tumor‐associated macrophages in immunotherapy
Yan, S., & Wan, G. (2021) · FEBS Journal · doi:10.1111/febs.15726 · Cited by 112
From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer
Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 108
Metadata
- Authors
- Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., Byrom, D., Matarin, J. A., Calon, A., Rivas, E. I., Nebreda, A. R., Riera, A., Attolini, C. S.-O., & Batlle, E.
- Affiliations
- Institute for Research in Biomedicine (ES)
- Universitat Autònoma de Barcelona (ES)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Batlle, Eduard
- ORCID
- Venue
- Nature
- Published
- 2018-02
- Volume
- 554
- Issue
- 7693
- Pages
- 538-543
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2788975052
- Cited by
- 1,851
- References
- 43
- Citations by year
- 2026: 193 · 2025: 186 · 2024: 159 · 2023: 211 · 2022: 280 · 2021: 305 · 2020: 247 · 2019: 176 · 2018: 94
- FWCI
- 77.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- TGF-beta signaling, colorectal cancer metastasis, immune evasion, T-cell exclusion, tumor microenvironment, immune checkpoint inhibitors, TGF-beta inhibition, liver metastasis, microsatellite stable colorectal cancer, genetically engineered mouse models, organoid transplantation, combination immunotherapy
- MeSH terms
- Alleles, Animals, Cell Differentiation, Colonic Neoplasms, Disease Models, Animal, Drug Synergism, Female, Humans, Immunotherapy, Intestinal Mucosa, Intestines, Liver Neoplasms, Male, Mutation, Neoplasm Metastasis, Stem Cells, T-Lymphocytes, Cytotoxic, Transforming Growth Factor beta, Th1 Cells, Mice, Immune Evasion, Tumor Microenvironment, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.